Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Filgotinib in Small Bowel Crohn's Disease
2016-003179-23Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Filgotinib with Placebo (2 arms). Primary endpoint: Clinical remission by CDAI. Started Feb 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-003179-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003179-23.